Fig. 2
From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Median Progression-Free Survival (a) and Overall Survival (b) Associated with Successive Lines of Chemotherapy (Versus no Treatment) in a Retrospective Analysis of Three Randomized Trials in Patients with Advanced Ovarian Cancer [19]. Data from Hanker et al. Ann Oncol. 2012;23:2605–12. Hanker et al. performed a retrospective, pooled analysis of three randomized, phase 3 studies of primary taxane-platinum-based chemotherapy. The analysis included 1620 patients for whom complete data were available. Responsiveness to platinum-containing regimens declined dramatically after 2 prior lines, even in patients who were initially platinum-sensitive [19]